#122 Why AI Drug Discovery Is So Hard — Dr Imran Haque (Recursion)

Big Picture Medicine

Mustafa Sultan, MD, Mustafa Sultan, and MD द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Mustafa Sultan, MD, Mustafa Sultan, and MD या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।

1y ago 40:32

MP3•एपिसोड होम

Despite $billions of investment into the sector — there are still no AI discovered drugs on the market. Why? Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the hottest AI drug discovery companies on the market. Especially after NVIDIA's $50M investment into them. Dr Imran Haque (SVP of AI and Digital Sciences) explains why AI drug discovery is so tricky — and when it's arriving. 0:00 Intro 0:42 Decoding biology (the big idea) 2:18 Why is AI drug discovery harder than it looks? 4:48 Simulating the Sims (game) vs AI drug discovery 6:58 Building data for AI drug discovery 14:47 Recursion's successes and failures 24:22 The barriers to AI drug discovery 26:45 How optimistic should we be about AI drug discovery 35:26 Being aggressively generalist for success People Dr Imran Haque: https://www.recursion.com/team-members/imran-haque Dr Imran Mahmud: https://www.imranmahmud.com/ Dr Mustafa Sultan: https://www.musty.io/

150 एपिसोडस

#Fitness #Medicine #Mustafa Sultan